[1]
|
Orth, M., Lauber, K., Niyazi, M., Friedl, A.A., Li, M., Maihöfer, C., et al. (2014) Current Concepts in Clinical Radiation Oncology. Radiation and Environmental Biophysics, 53, 1-29. https://doi.org/10.1007/s00411-013-0497-2
|
[2]
|
Baumann, M., Krause, M., Overgaard, J., Debus, J., Bentzen, S.M., Daartz, J., et al. (2016) Radiation Oncology in the Era of Precision Medicine. Nature Reviews Cancer, 16, 234-249. https://doi.org/10.1038/nrc.2016.18
|
[3]
|
Thomas, L. (1959) Cellular and Humoral Aspects of the Hypersensitive States: A Symposium Held at the New York Academy of Medicine. Hoeber-Harper, New York.
|
[4]
|
Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J. and Schreiber, R.D. (2002) Cancer Immunoediting: From Immunosurveillance to Tumor Escape. Nature Immunology, 3, 991-998.
|
[5]
|
Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity, 21, 137-148. https://doi.org/10.1016/j.immuni.2004.07.017
|
[6]
|
Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Three Es of Cancer Immunoediting. Annual Review of Immunology, 22, 329-360.
|
[7]
|
Vesely, M.D., Kershaw, M.H., Schreiber, R.D. and Smyth, M.J. (2011) Natural Innate and Adaptive Immunity to Cancer. Annual Review of Immunology, 29, 235-271.
|
[8]
|
Jiang, W., Chan, C.K., Weissman, I.L., Kim, B.Y.S. and Hahn, S.M. (2016) Immune Priming of the Tumor Microenvironment by Radiation. Trends in Cancer, 2, 638-645. https://doi.org/10.1016/j.trecan.2016.09.007
|
[9]
|
Kim, J.Y., Son, Y.O., Park, S.W., Bae, J.H., Chung, J.S., Kim, H.H., et al. (2006) Increase of NKG2D Ligands and Sensitivity to NK Cell-Mediated Cytotoxicity of Tumor Cells by Heat Shock and Ionizing Radiation. Experimental & Molecular Medicine, 38, 474-484.
|
[10]
|
Chakraborty, M., Abrams, S.I., Camphausen, K., Liu, K., Scott, T., Coleman, C.N., et al. (2003) Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy. The Journal of Immunology, 170, 6338-6347.
|
[11]
|
Filatenkov, A., Baker, J., Mueller, A.M., Kenkel, J., Ahn, G.O., Dutt, S., et al. (2015) Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 21, 3727-3739.
https://doi.org/10.1158/1078-0432.CCR-14-2824
|
[12]
|
Klug, F., Prakash, H., Huber, P.E., Seibel, T., Bender, N., Halama, N., et al. (2013) Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy. Cancer Cell, 24, 589-602. https://doi.org/10.1016/j.ccr.2013.09.014
|
[13]
|
Wang, Y., Deng, W., Li, N., Neri, S., Sharma, A., Jiang, W. and Lin, S.H. (2018) Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Frontiers in Pharmacology, 9, Article No. 185. https://doi.org/10.3389/fphar.2018.00185
|
[14]
|
Thomas, D.A. and Massague, J. (2005) TGF-β Directly Targets Cytotoxic T Cell Functions during Tumor Evasion of Immune Surveillance. Cancer Cell, 8, 369-380. https://doi.org/10.1016/j.ccr.2005.10.012
|
[15]
|
Gorelik, L. and Flavell, R.A. (2001) Immune-Mediated Eradication of Tumors through the Blockade of Transforming Growth Factor-Beta Signaling in T Cells. Nature Medicine, 7, 1118-1122. https://doi.org/10.1038/nm1001-1118
|
[16]
|
Heeran, A.B., Berrigan, H.P. and O’Sullivan, J. (2019) The Radiation-Induced Bystander Effect (RIBE) and Its Connections with the Hallmarks of Cancer. Radiation Research, 192, 668-679. https://doi.org/10.1667/RR15489.1
|
[17]
|
Turgeon, G.A., Weickhardt, A., Azad, A.A., Solomon, B. and Siva, S. (2019) Radiotherapy and Immunotherapy: A Synergistic Effect in Cancer Care. Medical Journal of Australia, 210, 47-53. https://doi.org/10.5694/mja2.12046
|
[18]
|
Krombach, J., Hennel, R., Brix, N., Orth, M., Schoetz, U., Ernst, A., Schuster, J., Zuchtriegel, G., Reichel, C.A. and Bierschenk, S. (2019) Priming Anti-Tumor Immunity by Radiotherapy: Dying Tumor Cell-Derived DAMPs Trigger Endothelial Cell Activation and Recruitment of Myeloid Cells. OncoImmunology, 8, e1523097.
https://doi.org/10.1080/2162402X.2018.1523097
|
[19]
|
McLaughlin, M., Patin, E.C., Pedersen, M., Wilkins, A., Dillon, M.T., Melcher, A.A. and Harrington, K.J. (2020) Inflammatory Microenvironment Remodelling by Tumour Cells after Radiotherapy. Nature Reviews Cancer, 20, 203-217. https://doi.org/10.1038/s41568-020-0246-1
|
[20]
|
Mehla, K. and Singh, P.K. (2019) Metabolic Regulation of Macrophage Polarization in Cancer. Trends in Cancer, 5, 822-834. https://doi.org/10.1016/j.trecan.2019.10.007
|
[21]
|
Yang, X., Guo, Y., Guo, Z., Si, T., Xing, W., Yu, W. and Wang, Y. (2019) Cryoablation Inhibition of Distant Untreated Tumors (Abscopal Effect) Is Immune Mediated. Oncotarget, 10, 4180-4191.
https://doi.org/10.18632/oncotarget.24105
|
[22]
|
Reynders, K., Illidge, T., Siva, S., Chang, J.Y. and De Ruysscher, D. (2015) The Abscopal Effect of Local Radiotherapy: Using Immunotherapy to Make a Rare Event Clinically Relevant. Cancer Treatment Reviews, 41, 503-510.
|
[23]
|
Hu, Z.I., McArthur, H.L. and Ho, A.Y. (2017) The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer? Current Breast Cancer Reports, 9, 45-51. https://doi.org/10.1007/s12609-017-0234-y
|
[24]
|
Sun, Z., Chen, F., Meng, F., Wei, J. and Liu, B. (2017) MHC Class II Restricted Neoantigen: A Promising Target in Tumor Immunotherapy. Cancer Letters, 392, 17-25. https://doi.org/10.1016/j.canlet.2016.12.039
|
[25]
|
Sethuraman, S.N. and Ranjan, A. (2016) Neoantigen Activation, Protein Translocation and Targeted Drug Delivery in Combination with Radiotherapy. Therapeutic Delivery, 7, 377-385. https://doi.org/10.4155/tde-2016-0005
|
[26]
|
Marconi, R., Strolin, S., Bossi, G. and Strigari, L. (2017) A Meta-Analysis of the Abscopal Effect in Preclinical Models: Is the Biologically Effective Dose a Relevant Physical Trigger? PLoS ONE, 12, e0171559.
https://doi.org/10.1371/journal.pone.0171559
|
[27]
|
Johnson, C.B. and Jagsi, R. (2016) The Promise of the Abscopal Effect and the Future of Trials Combining Immunotherapy and Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics, 95, 1254-1256.
|
[28]
|
Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., et al. (2015) Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer. Nature, 520, 373-377.
https://doi.org/10.1038/nature14292
|
[29]
|
Reits, E.A., Hodge, J.W., Herberts, C.A., Groothuis, T.A., Chakraborty, M., Wansley, E.K., et al. (2006) Radiation Modulates the Peptide Repertoire, Enhances MHC Class I Expression, and Induces Successful Antitumor Immunotherapy. Journal of Experimental Medicine, 203, 1259-1271. https://doi.org/10.1084/jem.20052494
|
[30]
|
Sato, H., Niimi, A., Yasuhara, T., Permata, T.B.M., Hagiwara, Y., Isono, M., et al. (2017) DNA Double-Strand Break Repair Pathway Regulates PD-L1 Expression in Cancer Cells. Nature Communications, 8, Article No. 1751.
https://doi.org/10.1038/s41467-017-01883-9
|
[31]
|
Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., et al. (2014) Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients. Nature, 515, 563-567.
https://doi.org/10.1038/nature14011
|
[32]
|
Sharabi, A.B., Lim, M., DeWeese, T.L. and Drake, C.G. (2015) Radiation and Checkpoint Blockade Immunotherapy: Radiosensitisation and Potential Mechanisms of Synergy. The Lancet Oncology, 16, E498-E509.
https://doi.org/10.1016/S1470-2045(15)00007-8
|
[33]
|
Zheng, X., Fang, Z., Liu, X., Deng, S., Zhou, P., Wang, X., et al. (2018) Increased Vessel Perfusion Predicts the Efficacy of Immune Checkpoint Blockade. The Journal of Clinical Investigation, 128, 2104-2115.
|
[34]
|
O’Donnell, J.S., Teng, M.W.L. and Smyth, M.J. (2019) Cancer Immunoediting and Resistance to T Cell-Based Immunotherapy. Nature Reviews Clinical Oncology, 16, 151-167. https://doi.org/10.1038/s41571-018-0142-8
|
[35]
|
Ozpiskin, O.M., Zhang, L. and Li, J.J. (2019) Immune Targets in the Tumor Microenvironment Treated by Radiotherapy. Theranostics, 9, 1215-1231. https://doi.org/10.7150/thno.32648
|
[36]
|
Liu, Y., Dong, Y., Kong, L., Shi, F., Zhu, H. and Yu, J. (2018) Abscopal Effect of Radiotherapy Combined with Immune Checkpoint Inhibitors. Journal of Hematology & Oncology, 11, Article No. 104.
https://doi.org/10.1186/s13045-018-0647-8
|
[37]
|
Levy, A., Chargari, C., Marabelle, A., Perfettini, J.L., Magné, N. and Deutsch, E. (2016) Can Immunostimulatory Agents Enhance the Abscopal Effect of Radiotherapy? European Journal of Cancer, 62, 36-45.
|
[38]
|
Shaverdian, N., Lisberg, A.E., Bornazyan, K., et al. (2017) Previous Radiotherapy and the Clinical Activity and Toxicity of Pembrolizumab in the Treatment of Non-Small-Cell Lung Cancer: A Secondary Analysis of the KEYNOTE-001 Phase 1 Trial. The Lancet Oncology, 18, 895-903. https://doi.org/10.1016/S1470-2045(17)30380-7
|
[39]
|
Maity, A., Mick, R., Huang, A.C., et al. (2018) A Phase I Trial of Pembrolizumab with Hypofractionated Radiotherapy in Patients with Metastatic Solid Tumours. British Journal of Cancer, 119, 1200-1207.
https://doi.org/10.1038/s41416-018-0281-9
|
[40]
|
Young, K.H., Baird, J.R., Savage, T., Cottam, B., Friedman, D., Bambina, S., et al. (2016) Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy. PLoS ONE, 11, e0157164.
https://doi.org/10.1371/journal.pone.0157164
|
[41]
|
Antonia, S.J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., et al. (2017) Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 377, 1919-1929.
|
[42]
|
Lee, Y., Auh, S.L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., et al. (2009) Therapeutic Effects of Ablative Radiation on Local Tumor Require CD8+ T Cells: Changing Strategies for Cancer Treatment. Blood, 114, 589-595.
https://doi.org/10.1182/blood-2009-02-206870
|
[43]
|
Lugade, A.A., Moran, J.P., Gerber, S.A., Rose, R.C., Frelinger, J.G. and Lord, E.M. (2005) Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells that Traffic to the Tumor. The Journal of Immunology, 174, 7516-7523. https://doi.org/10.4049/jimmunol.174.12.7516
|
[44]
|
Kim, M.S., Kim, W., Park, I.H., Kim, H.J., Lee, E., Jung, J.H., et al. (2015) Radiobiological Mechanisms of Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery. Radiation Oncology Journal, 33, 265-275.
https://doi.org/10.3857/roj.2015.33.4.265
|
[45]
|
Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine, 372, 2509-2520.
|
[46]
|
Khagi, Y., Goodman, A.M., Daniels, G.A., Patel, S.P., Sacco, A.G., Randall, J.M., et al. (2017) Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 23, 5729-5736.
https://doi.org/10.1158/1078-0432.CCR-17-1439
|
[47]
|
Gopalakrishnan, V., Spencer, C.N., Nezi, L., Reuben, A., Andrews, M.C., Karpinets, T.V., et al. (2018) Gut Microbiome Modulates Response to Anti-PD-1 Immunotherapy in Melanoma Patients. Science, 359, 97-103.
|